Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Technology appraisal guidance
Reference number: TA927
Published: 17 October 2023

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Published:

07 September 2023

Declaration of interests

Register of interests (PDF 155 KB)

Published:

17 October 2023

Final draft guidance

Final draft guidance
Final draft guidance (PDF 263 KB)

Published:

07 September 2023
Committee papers (PDF 12.05 MB)

Published:

07 September 2023
Public committee slides (PDF 1.08 MB)

Published:

07 September 2023

Invitation to participate

Final scope (PDF 207 KB)

Published:

28 November 2022
Final stakeholder list (PDF 189 KB)

Published:

28 November 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 198 KB)

Published:

28 November 2022
Equality impact assessment (Scoping) (PDF 121 KB)

Published:

28 November 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: Cancer

Draft matrix post referral (PDF 195 KB)

Published:

10 October 2022
Draft scope post referral (PDF 218 KB)

Published:

10 October 2022